List view / Grid view
The cancer therapeutic, Rozlytrek, has gained FDA approval as well…
The cancer therapeutic, Rozlytrek, has gained FDA approval as well as Priority Review, Breakthrough Therapy and Orphan Drug Designations.
Roche announced positive results from the Phase III GADOLIN study,…
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...
Roche presented data from a first-in-patient study of the novel…
9 December 2014 | By Roche
Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting...
Roche announced that the U.S. Food and Drug Administration has…
9 October 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted to file the company's supplemental Biologics License Application and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans...
Roche announced that important new data from its established and…
17 September 2014 | By Roche
Roche announced that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain...
Roche announced that phase III clinical studies have been initiated…
15 September 2014 | By Roche
Roche announced that phase III clinical studies have been initiated for lampalizumab, an investigational drug for geographic atrophy, the advanced form of age-related macular degeneration, a progressive condition which can result in blindness...
Avastin is the first biologic medicine approved in combination with…
15 August 2014 | By Roche
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone...
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab)…
29 July 2014 | By Roche
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy...
Roche announced that the U.S. Food and Drug Administration has…
15 July 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer...
Data showed that over 90 percent of Japanese people in…
4 July 2014 | By Roche
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib...
Roche announced that the EU Committee for Medicinal Products for…
27 June 2014 | By Roche
Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve the use of Avastin® (bevacizumab)...
Roche announced that the EU Committee for Medicinal Products for…
23 May 2014 | By Roche
Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukemia...
First anti IL-6 receptor biologic now available for subcutaneous and…
28 April 2014 | By Roche
First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy...
Roche announced that the U.S. Food and Drug Administration approved…
24 March 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives...
Roche presented new data from the LUTE / VERSE phase…
5 March 2014 | By Roche
Roche presented new data from the LUTE / VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma...
